Austria has gained an outstanding reputation as a research location in the field of life sciences – both as a vibrant hub for science and as a cluster for research-oriented and manufacturing companies. The ABA links international companies with this ecosystem

British drug discovery specialist BenevolentAI Ltd has licenced its end-to-end AI platform capabilities to Merck KGaA to deliver novel drug candidates for three targets in oncology, neurology and immunology.
 

Autoimmunity specialist AbolerIS Pharma will use a €27.3m Series A Financing to advance its first-in-class antibody inducing immune tolerance in rheumatoid arthritis into the clinic.

The Cultivated B ist the first company in the world to apply for EU-Novel-Food authorisation of a hotdog made from plant protein and cultivated muscle cells.

A Belgian-British research team has identified the human protein underlying necroptosis of human brain cells in Alzheimer’s mice and stopped cell death.

French pharma company Pierre Fabre Laboratories has baged Vertical Bio to push development of the company’s NSCLC candidate.

C

French-US-based investment specialist Lauxera Capital Partners announced today that it has invested €17m in Swedish cell culture company BioLamina AB (BioLamina)

Orano Med SAS and Orbit Discovery Ltd announced a collaboration to develop Peptide Receptor Radionuclide Therapies for cancer cells and develop novel radiopharmaceuticals.

London-based Engitix Ltd has appointed a new Chief Scientific Officer (CSO). Christopher Stevenson, Ph.D. took over the position at the beginning of September.

Eva Schlintl joined the LISAvienna team at the beginning of September. Most recently, she managed the LISA – Life Science Austria programme of Austria Wirtschaftsservice Gesellschaft mbH (aws).